Clinical Trial

Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer

NEEDHAM, Mass., May 28, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical…

7 months ago

Celly Nutrition Retains Leading Audit Firm MNP LLP to Advance Capital Raise and Go-Public Readiness and Changes Name to Unbuzzd Wellness Inc.

Toronto, Ontario--(Newsfile Corp. - May 28, 2025) - Unbuzzd Wellness Inc. (formerly, Celly Nutrition Corp.) (the "Company"), the company behind…

7 months ago

QI Path Launches AI-driven Risk Intelligence Platform To Transform Risk Mitigation and Regulatory Readiness Across the Drug Development Lifecycle

BOULDER, Colo., May 27, 2025 /PRNewswire/ -- In response to the mounting regulatory, operational, and reputational pressures facing pharmaceutical companies and…

7 months ago

STORM Therapeutics Announces First Patient Dosed in Clinical Collaboration to Evaluate STC-15 in Combination with LOQTORZI® and Appointment of Atif Abbas, M.D., as Chief Medical Officer

STC-15 has demonstrated durable clinical activity and tolerability to progress into a combination study with a checkpoint inhibitor  Collaboration enables…

7 months ago

Mangoceuticals’ Patented MGX-0024 Delivers 100% Respiratory Survival in Poultry Studies Signaling Strong Potential Defense Against Spread of Avian Flu

Dallas, TX, May 27, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company"), a company focused on…

7 months ago

VIVUS Announces QSYMIA® Now Available at Costco Pharmacies Nationwide

— Expanded retail access aims to enhance overweight or obesity treatment accessibility CAMPBELL, Calif., May 27, 2025 (GLOBE NEWSWIRE) --…

7 months ago

NurExone Biologic Inc. Announces First Quarter 2025 Financial Results and Provides Corporate Update

TORONTO and HAIFA, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“ NurExone ”…

7 months ago

Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting

Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with improved pathologic response.ROCHESTER, N.Y., May 27,…

7 months ago

Teva and Biolojic Design Initiate IND-enabling Studies of BD9, a Multibody Designed to Explore the Treatment of Atopic Dermatitis and Asthma

BD9 is a multibody that targets IL-13 and TSLP, and has potential to treat TH-2-driven inflammatory diseasesBD9 designed using Biolojic’s…

7 months ago